공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

전이성 유방암 : 세계 임상시험 리뷰

Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017

리서치사 GlobalData
발행일 2017년 12월 상품 코드 230753
페이지 정보 영문 1674 Pages
가격
US $ 2,500 ₩ 2,825,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,651,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,477,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


전이성 유방암 : 세계 임상시험 리뷰 Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017
발행일 : 2017년 12월 페이지 정보 : 영문 1674 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

전이성 유방암(Metastatic Breast Cancer) 치료제에 관한 임상시험의 최신 동향에 대해 분석했으며, G7(주요 7개국) 및 E7(신흥 7개국)의 임상시험 건수, 피험자수, 유망한 스폰서, 임상시험에 참여하고 있는 주요 기업과 기관, 유망한 약제 등의 정보를 전해드립니다.

본 보고서의 개요

각 지역의 임상시험 상황

  • 각국의 임상시험 건수와 평균 피험자수
    • 아시아태평양 지역 주요 5개국의 임상시험 건수
    • 유럽 주요 5개국의 임상시험 건수
    • 북미 주요 국가의 임상시험 건수
    • 중동 및 아프리카 주요 5개국의 임상시험 건수
    • 중남미 주요 5개국의 임상시험 건수

G7 국가의 임상시험 건수 : 암 치료제 임상시험에서 전이성 유방암의 비율

G7 국가의 단계별 임상시험 건수

G7 국가의 임상시험 건수 : 진행 상황별

E7 국가의 임상시험 건수 : 암 치료제 임상시험에서 전이성 유방암의 비율

E7 국가의 단계별 임상시험 건수

E7 국가의 임상시험 건수 : 진행 상황별

단계별 임상시험 건수

  • 진행중인 임상시험 : 단계별

진행 상황별 임상시험 건수

임상시험 목표 달성 상황

일정기간에 채용된 피험자

스폰서 종류별 임상시험 건수

유망한 스폰서

전이성 유방암 치료제 임상시험에 참여하고 있는 주요 기업

유망한 약제

최신 임상시험 뉴스

임상시험 프로파일 개요

부록

KSM 16.10.04

GlobalData's clinical trial report, "Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Metastatic Breast Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Breast Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Metastatic Breast Cancer Therapeutics Clinical Trials 29
  • Prominent Drugs 30
  • Latest Clinical Trials News on Metastatic Breast Cancer 31
  • Dec 08, 2017: Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer 31
  • Dec 07, 2017: Prolonged Progression-Free Survival Reinforces Tucatinib's Potential for Patients with Advanced HER2+ Metastatic Breast Cancer 31
  • Dec 07, 2017: Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium 32
  • Dec 07, 2017: Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium 33
  • Dec 06, 2017: Updated Data From Phase 3 Trial Of IBRANCE (Palbociclib) Plus Letrozole In Er+, Her2- Metastatic Breast Cancer Confirm Improvement In Progression-Free Survival 33
  • Dec 06, 2017: Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC) 34
  • Dec 05, 2017: Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium 35
  • Dec 05, 2017: New Scientific Publication Supports Agilvax's Novel Immunotherapy Development for Metastatic Breast Cancer 36
  • Dec 04, 2017: Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression 36
  • Dec 04, 2017: Oncolytics Biotech to Present at the Oncolytic Virotherapy Summit 36
  • Nov 30, 2017: New and Updated Data for Merck's KEYTRUDA (pembrolizumab) in Multiple Breast Cancer Subtypes to be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) 37
  • Nov 30, 2017: Updated Data on LYNPARZA (olaparib) in Multiple Breast Cancer Subtypes to be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) 38
  • Nov 14, 2017: Daiichi Sankyo to Present Updated DS-8201 Data at SABCS 38
  • Nov 13, 2017: Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium 38
  • Nov 08, 2017: Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer 39
  • Nov 08, 2017: ASLAN Pharmaceuticals Announces Poster Presentation at ESMO Asia Congress 2017 39
  • Nov 06, 2017: Tyme Announces Encouraging Efficacy and Safety Data from First Human Study of SM-88 in Women with Metastatic Breast Cancer 40
  • Oct 31, 2017: Dr. Frederic Triebel Presented at the World Immunotherapy Congress 2017 41
  • Oct 31, 2017: Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain 41
  • Oct 19, 2017: RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 41
  • Oct 19, 2017: BerGenBio Announces Start of Phase II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer 42
  • Oct 11, 2017: Oncolytics Biotech to Present at the 2017 BIO Investor Forum 42
  • Oct 06, 2017: Lilly MONARCH 3 Study Published In Journal Of Clinical Oncology Demonstrates Benefit Of Verzenio (Abemaciclib) Plus NSAI In Advanced Breast Cancer 42
  • Oct 05, 2017: Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin 43
  • Oct 05, 2017: Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program 44
  • Sep 22, 2017: Eisai Presents Latest Non-Clinical Data On Its First Antibody-Drug Conjugate MORAb-202 At 8th Annual World ADC 44
  • Clinical Trial Profile Snapshots 45

Appendix 1671

  • Abbreviations 1671
  • Definitions 1671
  • Research Methodology 1672
  • Secondary Research 1672
  • About GlobalData 1673
  • Contact Us 1673
  • Disclaimer 1673
  • Source 1674

List of Tables

List of Tables

  • Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Metastatic Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Metastatic Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Metastatic Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Metastatic Breast Cancer Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Metastatic Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Metastatic Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 16
  • Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 19
  • Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Metastatic Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Metastatic Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
Back to Top
전화 문의
F A Q